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Abstract Endothelial cell (EC) injury or dysfunction is
believed to be mediated at least in part by lipopolysac-
charide (LPS). Recent studies have shown that LPS induces
apoptosis in different types of endothelium, including
HUVEC. Previously we used EOLA1 (endothelial-over-
expressed LPS-associated factor 1) cDNA as a bait and
performed a yeast two-hybrid screening of a human liver
cDNA library and identified metallothionein 2a (MT2a) as
the associated protein. EOLA1 protein plays a role as a
signal transduction factor. But the mechanism of EOLA1
mediated the protection of cell production of IL-6 and
apopotosis in HUVEC is not known. MT2a is expressed in
many kinds of cells and plays a role in inflammation. In
this study, we demonstrated that LPS could induce EOLA1
expression in time-dependent and apparently contributed to
the inhibition of IL-6 production and apoptosis induced by
LPS treatment. We also found that deletion of EOLA1
promoted IL-6 production and apoptosis in the treatment of
LPS in HUVEC. Furthermore, we demonstrated that MT2a
was activated by LPS, and played a key role in LPS-
induced IL-6 expression in HUVEC. We further provided
the evidence that EOLA1 functioned as a negative regu-
lator for LPS response by regulation of MT2a. These
findings suggest that EOLA1 may have an important reg-
ulatory role during EC inflammatory responses.
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Introduction
Endothelial cell (EC) injury and/or dysfunction, a com-
monality among several key complications associated with
septic shock, is believed to be mediated at least in part by
lipopolysaccharide (LPS). LPS, a complex glycoprotein
constituent of the outer cell wall of Gram-negative bacte-
ria, has been implicated in endothelial injury that leads to
septic shock and its associated syndromes [1–5]. Recent
studies have shown that LPS induces apoptosis in different
types of endothelium, including HUVEC and lung-derived
normal human microvascular endothelial cells [6–9]. LPS
administration has also been shown to cause apoptosis in B
cells thymocytes, and lymphoid organs [10, 11]. Enhanced
apoptotic cell death has also been shown in various tissues
derived from patients who have died due to sepsis or
multiorgan failure. LPS directly activates the vascular
endothelium and elicits an array of EC responses, including
an increase in the expression of specific adhesion mole-
cules and inflammatory cytokines such as IL-1, IL-8, and
MCP-1 (monocyte chemotactic protein-1), which in turn
results in the selective recruitment of leukocytes to
inflammatory foci [12, 13]. Previous studies have also
reported that release of LPS into the circulation induces
endothelial apoptosis in vivo and thus causes microvascu-
lar injury in numerous tissues, including lung, gut, and
liver, during sepsis [1–3]. Enhanced apoptotic cell death
has also been shown in various tissues derived from
patients who have died due to sepsis or multiorgan failure.
Apoptotic endothelial cells have also been detected in
murine models of sepsis [4, 12].
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EOLA1, named as endothelial-overexpressed LPS-
associated factor 1 (also named as Cxorf40A), is 1404 bp
long, encoding a 158aa, 17.8 kDa protein, mapped to
chromosome Xq27.4 with 5 exons EOLA1 was mainly
expressed in E. coli as insoluble inclusion bodies. The
protein content in the primary extracted inclusion bodies
accounted for over 75 %, and it accounted for more than
90 % after chromatography and renaturation [13]. It is
expressed primarily in heart, skeletal muscle, kidney, liver
and placenta. Relatively high level of expression in spleen,
colon and small intestine and also cancer cell lines. Almost
no expression in brain, thymus, lung and peripheral blood
leukocytes. Previous report showed that EOLA1 protein is
localized in the nucleus and the matrix of ECV304 cells,
and it plays a role as a signal transduction factor [14, 15].
EOLA1 could inhibit the proliferation of human umbilical
vein EC line ECV304 [16, 17].
Metallothioneins (Mts) are a family of proteins with a
high affinity to certain metal ions such as zinc and cad-
mium. Mts proteins are expressed in multiple organs and
exist in several isoforms subdivided in four groups Mt1,
Mt2, Mt3 and Mt4. Mts may have a role in the regulation of
zinc and copper homeostasis and act as potent antioxidants
against oxidative damage [18, 19]. MT2a is one of the
famliy and express in many kinds of cells such as 3T3-L1
adipocytes, cancer cells [20–22]. A significant association
between rs28366003 genotype and MT2a expression level
is found in prostate cancer patients and other cells. MT2a
has various functions including involving in insulin resis-
tance in fat cells; predicting poor outcome in non-small cell
lung cancer [23–28]. EOLA1 and MT2a may have an
important role of cell protection in inflammation reaction.
To investigate the role of EOLA1 in LPS induced IL-6
production and apoptosis, this study was designed to
examine their possible contribution to LPS-stimulated IL-6
expression in HUVEC. We demonstrated, for the first time,
that EOLA1 expression was induced by LPS in HUVEC,
and apparently contributed to the inhibition of IL-6
induction by LPS treatment. Furthermore, we found that
EOLA1 inhibited LPS-induced IL-6 expression and apop-
tosis in HUVEC by MT2a. The data suggest that EOLA1




HUVEC cell line was purchased from ATCC (Manassas,
VA, USA). Cells were grown at 37 C in 5 % CO2 in
endothelial growth medium (EGM-2-MV) containing 2 %
FBS, 12 lg/ml bovine brain extract, 10 ng/ml human
recombinant epidermal growth factor, 1 lg/ml hydrocor-
tisone, GA-1000 (gentamicin and amphotericin B, 1 lg/
ml), according to the recommendations of the supplier.
siRNA treatment
Knockdown of EOLA1 and MT2a was accomplished using
siRNA (synthesized by Genepharma, Shanghai, China).
EOLA1 siRNA target sequence was: 50-AAGTGGAA-
GAGTGTTTCCTCC-30 and MT2a siRNA target sequence
was: 50-AAGTGCAGCTGCTGCGCCTGA-30. Approxi-
mately 2 9 105 cells were seeded per well of a 6-well
tissue culture dish the day before transfection. Transfection
was performed according to the manufacturer’s instructions
using lipofectamine-2000 reagent and 100nM siRNA.
Efficient knockdown was checked three day post-trans-
fection of siRNA by RT-PCR and Western blotting.
Cytokines assay
The cells were homogenized in PBS (1:2, w/v) containing
1 % protease inhibitors and then centrifuged at
12,000 9 g for 15 min at 4 C. The supernatants were
analyzed for IL-6 using ELISA kit (Roche, USA) accord-
ing to the manufacturer’s instructions.
RNA isolation and real-time RT-PCR
Total RNA, following the manufacturer’s instructions, was
isolated from the cells using Trizol reagent (Invitrogen).
Briefly, the cells were lysed in TRIzol and then mixed with
chloroform. The lysate was centrifuged to separate RNA, DNA
and protein, total RNA recovered, precipitated with isopropa-
nol, washed in 75 % ethanol to remove impurities before dis-
solved in water. After that, 2 lg of RNA was taken and treated
with DNase to remove contaminating DNA prior to the reverse
transcription to cDNA. To measure mRNA expression, real-
time RT-PCR was performed using a sequence detector (ABI-





-30. The relative expression levels were calculated by com-
paring Ct values of the samples with those of the reference, all
data normalized to the internal control GAPDH.
Construction of EOLA1 vector, lentivirus production
and infection
The full-length human EOLA1 cDNA sequence was ampli-
fied by PCR of EOLA1 vector (OriGene, MD, USA) and
subcloned into the lentivirus vector (Invitrogen) for the
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generation of EOLA1 vector. The construct was verified by
sequencing. The lentivirus was produced according to the
manufacturer’s instructions: DNA–Lipofectamine 2000
complexes were prepared containing 3 mg of lentivirus vector
expression plasmid DNA and 9 mg of the ViraPower Pack-
aging Mix in 1.5 ml of Opti-MEM I medium without serum;
the packaging cell 293FT was trypsinized and counted and the
cells were resuspended at a density of 106 cells/ml in growth
medium containing serum; the DNA–Lipofectamine 2000
complexes were added to a 10-cm culture plate containing
5 ml of growth medium with serum; 5 ml 293FT cells were
added to the plate and mixed gently by rocking. On the next
day, the media containing the DNA–Lipofectamine 2000
complexes were removed and replaced with complete culture
medium, and virus-containing supernatants 48 h post-trans-
fection were harvested and centrifuged at 3,000 rpm for 5 min
at 48 C to pellet debris, and the virus was concentrated at
20,000 rpm and stored at -70 C, lentiviral vectors were ti-
tered in the cells based on the protocols.
Determination of apoptosis by flow cytometry
For apoptosis assay, the AnnexinnV straining was quanti-
fied by flow cytometric. The cells were plated in a 6-well
plate, transfected with the indicated plasmid or siRNA, at
24 h later, the complete growth medium were changed to
growth medium without serum. At another 24 h later, the
cells were collected, washed in cold PBS twice and
resuspended in 19 binding buffer at a concentration of
1 9 106 cells/ml. After that, the cells in 100 ll solution
were transferred to a 5 ml culture tube, with 5 ll Annexin
V-FITC and 5 ll PI (BD Biosciences) added, and gently
vortexed and incubated for 15 min at RT in the dark. And
finally, 400 ll 19 binding buffer was added to each tube to
be analyzed by flow cytometry within 1 h.
Western blotting
The cells were scraped from the dishes, cellular protein
extracts prepared by homogenization in an ice-cold lysis
buffer and their lysates obtained by centrifugation at
12,000 9 g for 20 min, and the total protein concentration
determined using Lowry method. Equal amounts of pro-
tein, separated by SDS-PAGE, were electrophoretically
transferred to a PVDF membrane at 320 mA for 2 h at a
low temperature and the membrane was blocked with 5 %
fat-free milk with 0.05 % Tween 20 in PBS. Subsequently,
the membrane was probed with the primary antibodies. The
blots were washed in PBST and then incubated in anti-
mouse IgG or anti-rabbit IgG secondary antibody for about
3 h at RT. Washed in PBST (93, 10 min each wash), the
proteins were finally visualized using ECL based on the
manufacturer’s instructions.
Statistical analysis
Each experiment was repeated at least three times, Stu-
dent’s t tests performed to determine the statistical signif-
icance for the assays of ELISA and real time RT-PCR,
error bars representing ± SE.
Results
LPS induces IL-6 production and EOLA1 expression
in HUVEC
To examine the modulation of IL-6 secretion from endo-
thelial cells on LPS treatment, HUVEC were grown to
Fig. 1 LPS induces IL-6 production and EOLA1 in human umbilical
vein endothelial cells (HUVEC). a HUVEC were treated with LPS
(100 ng/ml) for various periods of time 0, 4, 8, 16 h and the
supernatants were collected and assayed for IL-6 production by
ELISA. b HUVEC were treated with various doses of LPS 0, 1, 10, 50
and 100 ng/ml for 16 h and he supernatants were collected and
assayed for IL-6 production by ELISA. Data represent the
mean ± S.D of three independent experiments. c LPS induces
EOLA1 expression in HUVEC. Cells were stimulated with LPS
(100 ng/ml) for the indicated periods of time. The lysates were
analyzed by Western blotting with antibodies to EOLA1. Data show
one representative experiment out of three independent experiments
Mol Cell Biochem (2014) 395:45–51 47
123
80 % confluence. These cells were stimulated with LPS for
the indicated periods. IL-6 concentrations in the clarified
culture supernatants were then measured by ELISA.
Exposure of HUVEC to LPS (100 ng/ml) resulted in a
significantly greater increase in IL-6 production compared
to HUVEC (Fig. 1a). Up-regulation of IL-6 in cells was
time-dependent (Fig. 1a) and dose-dependent (Fig. 1b).
Previous report showed that EOLA1 protein is localized
in the nucleus and the matrix of ECV304 cells, and it plays
a role as a signal transduction factor. EOLA1 could inhibit
the proliferation of human umbilical vein EC line ECV304.
To investigate the signaling processes involved in LPS-
induced IL-6 production, HUVEC was stimulated with
100 ng/ml LPS for different lengths of time and showed
that EOLA1 was decreased in time-dependent (Fig. 1c).
Deletion of EOLA1 increased the expression of IL6
and apoptosis induced by LPS in HUVEC
To further research the role of EOLA1 in HUVEC, the cells
were transfected with EOLA1 siRNA to observe expres-
sion of IL-6. EOLA1 was down-regulated in the HUVEC
with siRNA (Fig. 2a). The cells with depletion of EOLA1
were treated with LPS (100 ng/ml) at the point of 48 h
post-transfection and IL6 was detected by ELISA assay 6 h
after LPS induced. The results showed that LPS could
induce IL6 expression, knocking down of EOLA1
increased the expression of IL6 of HUVEC cells induced
by LPS in HUVEC cells (Fig. 2b). The cells with depletion
of EOLA1 were treated with LPS (100 ng/ml) at the point
of 48 h post-transfection and IL6 was detected by ELISA
assay 24 h after LPS induced. The results showed that
knocking down of EOLA1 increased apoptosis of HUVEC
cells induced by LPS in HUVEC cells (Fig. 2c). These
results meant that EOLA1 could inhibit the expression of
IL-6 and apoptosis in HUVEC cells induced by LPS.
Overexpression of EOLA1 inhibited the expression
of IL6 and apoptosis induced by LPS in HUVEC
To further research the role of EOLA1 in HUVEC, the cells
were transfected with lentivirus mediated EOLA1 to
observe expression of IL-6. EOLA1 was overexpressed in
the HUVEC (Fig. 3a). The cells with depletion of EOLA1
were treated with LPS (100 ng/ml) at the point of 48 h
post-infection and IL6 was detected by ELISA assay 6 h
after LPS induced. The results showed that LPS could
induce IL6 expression, knocking down of EOLA1
increased the expression of IL6 of HUVEC cells induced
by LPS in HUVEC cells (Fig. 3b). The cells with depletion
of EOLA1 were treated with LPS (100 ng/ml) at the point
of 48 h infection and IL6 was detected by ELISA assay
24 h after LPS induced. The results showed that EOLA1
inhibited apoptosis of HUVEC cells induced by LPS in
HUVEC cells (Fig. 3c). These results verified that EOLA1
could inhibit the expression of IL-6 and apoptosis in HU-
VEC cells induced by LPS. The data suggested that
EOLA1 might play a role in stress such as inflammation
reaction.
EOLA1 regulated IL-6 production through MT2a
To investigate the mechanism by which EOLA1 mediates
IL-6 production, we focused on MT2a. Our previous work
Fig. 2 Inhibition of EOLA1 with siRNA inhibits LPS-induced IL-6
production and induces apotosis in HUVEC. a HMVEC were
transfected with control or EOLA1 siRNA (200 nM) for 48 h at
37 C. The cells were lysed and analyzed by Western blotting with
EOLA1 antibody. b HMVEC were transfected with control or
EOLA1 siRNA (200 nM) for 24 h at 37 C and then cultured with or
without LPS (100 ng/ml) and the concentration of IL-6 in the culture
supernatants was determined 16 h after stimulation. Data represent
the mean ± S.D of three independent experiments. (C) HMVEC cells
pre-treated with EOLA1 siRNA were stimulated with LPS (100 ng/
ml) for 16 h. The supernatants were then tested for apoptosis.
(**P \ 0.01, *P \ 0.05)
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showed that MT2a was an associated protein may be
related to EOLA1. To explore whether EOLA1 regulates
the expression of MT2a, MT2a protein and mRNA were
measured by Western Blot and Real time PCR after cells
were transfected with EOLA1 siRNA. The results showed
that knocking down of EOLA1 could inhibit the expression
of MT2a significantly (Fig. 4a, b). This result indicated that
EOLA1 regulated the expression of MT2a in HUVEC
cells. To study whether MT2a involves in the IL-6 pro-
duction by LPS, the cells with depletion of MT2a were
treated with LPS (100 ng/ml) at the point of 48 h post-
transfection and IL6 was detected by ELISA assay 6 h after
LPS induced. The results showed that knocking down of
MT2a increased the expression of IL6 of HUVEC cells
induced by LPS in HUVEC cells (Fig. 4c). The cells with
Fig. 3 Transduction of HMVECs with EOLA1 prevents LPS induced
IL-6 production and inhibits apoptosis. HMVEC cells were trans-
duced with lentivirus mediated EOLA1. a Overexpression of the
EOLA1 was demonstrated by Western blot analysis with anti-EOLA1
antibody 48 h after transduction. b Transduced cells were tested for
their ability to produce IL-6 upon LPS stimulation (100 ng/ml) using
a commercial ELISA kit. c Apoptosis was tested by flow cytometry.
Data represent the mean ± S.D of three independent experiments.
(**P \ 0.01, *P \ 0.05)
Fig. 4 EOLA1 mediates LPS induced IL-6 production and inhibits
apoptosis by MT2a. a HUVEC was transfected with EOLA1 siRNA
or control siRNA, and the cells were lysed and analyzed by Western
blotting with anti-MT2a antibody. b HUVEC was transfected with
MT2a siRNA or control siRNA, and total RNA was isolated and
analyzed by real tim RT-PCR. c HUVEC was transfected with MT2a
siRNA or control siRNA, and the cells were lysed and analyzed by
Western blotting with anti-MT2a antibody. d HMVEC was transfec-
ted with MT2a siRNA or control siRNA and then stimulated with LPS
(100 ng/ml)for 16 h. IL-6 production was assayed by ELISA.
(**P \ 0.01, *P \ 0.05)
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depletion of EOLA1 were treated with LPS (100 ng/ml) at
the point of 48 h post-transfection and apoptosis was
detected by flow cytometry after LPS induced. The results
showed that knocking down of MT2a increased apoptosis
of HUVEC cells induced by LPS in HUVEC cells
(Fig. 4d). These results meant that EOLA1 could inhibit
the expression of IL-6 and apoptosis in HUVEC cells
induced by LPS through MT2a.
Discussion
A great mount of research results show that vascular EC
damage is the important factors led to shock and multior-
gan injury. Overactivation of endothelial cells can result in
uncontrolled inflammation. It is known that ischemia,
hypoxia, and endotoxin can make endothelial cells in the
stress, however, the mechanism is not clear.
The bacterial endotoxin, LPS stimulates endothelial
cells to express chemokines that initiate the activation and
recruitment of circulating leukocytes at inflammatory tis-
sue sites [29, 30]. But the effects of LPS on cytokine
production in endothelial cells are well elucidated, the
mechanism involved in this process has not been charac-
terized in detail. Hence we questioned whether EOLA1 has
a role in LPS-induced production of IL-6, attempting to
elucidate the molecular mechanism involved in this path-
way. Here, we demonstrate EOLA1 mediates LPS-induced
IL-6 production. Our experiments demonstrate that LPS
increases EOLA1 in microvascular endothelial cells. The
involvement of EOLA1 in LPS-induced IL-6 production
was confirmed using multiple strategies, namely LV-
expressing EOLA1 and EOLA1-specific siRNA.
Previous study showed that EOLA1 expression is asso-
ciated with vascular endothelial cells stimulated by LPS and
may involved in the process of activation of endothelial cells
and its damage [15, 31]. EOLA1 could protect endothelial
cells inflammation and LPS could induce EOLA1 expres-
sion. EOLA1 is relatively novel gene, which was discovered
in recent years and its function is not clear. Previous research
indicated that it is expressed in various of cells which indi-
cated it may play important role in the cells. Our data sug-
gested that EOLA1 might induce apoptosis resistance and
protect the endothelial cells in the stress. The results were
consistent with the previous report. So it is a protecting
molecule of cells. These indicates that EOLA1 plays
important roles in cell injury, wounding and stress reaction.
Based on EOLA1’s secondary structure, EOLA1 is
predicted to have the phosphorylated sites of tyrosine
kinase and protein kinase C and HTH motif, which might
make it has the ability of signal transduction. EOLA1 may
play an important role in activate endothelial cells induced
by LPS. EOLA1 is strongly expressed in many tissues such
as heart, bone, kidney, liver and placenta weakly expressed
in colon, small intestine and spleen, however almost no
expression in brain, thymus, lung, and peripheral white
blood cells. All of these indicates that EOLA1 is preferred
to expressing in the tissues with rich blood. MT2a is an
important stressful protection protein and induced by LPS,
which involves in cell proliferation, differentiation. The
relationship of EOLA1 and MT2a and their sublocation in
the cells suggested that EOLA1 might be transcription
factor associated with cell activation stimulated by LPS.
Taken together, we reported here that EOLA1 in HUVEC
dramatically decreased inflammation factor IL-6 production
and apoptosis induced by LPS treatment. Our finding is the
first demonstration that EOLA1 expression has a functional
role in inflammation of HUVEC. Our studies indicate that
EOLA1 may function as an important regulator in protection
of HUVEC injury in inflammatory diseases.
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